Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Cellia Science, Inc.
- Proposal award date
- 2023-02-15
- Contract end date
- 2023-11-15
- UEI
- M4PEEHE4DJJ3
- Solicitation number
- PA21-259
- Topic code
- NHLBI
Research abstract
Project Summary/Abstract
Evaluation for neutropenia and/or thrombocytopenia requires a 5-part white blood cell (WBC) differential with
platelet count. Currently, instruments capable of these measurements must be operated in a CLIA-certified
laboratory and rely on complex workflows involving multiple reagents, extensive calibration and maintenance,
and operation by highly trained personnel. Turnaround times of hours or days delay administration of critical
treatments, such as chemotherapy, anti-psychotic medications, and blood transfusions. Cellia Science will
address the need for more rapid blood cell differential tests and develop a device to diagnose neutropenia and
thrombocytopenia suitable for point-of-care or low-resource settings. This device will implement label-free deep
UV imaging combined with microfluidic “blood smear” preparation and cell classification algorithms to perform
blood cell differentials. Cellia’s deep UV images are pseudo-colorized and appear similar to Giemsa-stained
images, the current gold standard for manual differentials. However, because we are directly detecting the
nucleic acids in the cells, our images are inherently quantitative nucleic acid mass maps with subcellular detail
and femtogram sensitivity. In Phase I of this project, we will develop a microfluidic sample cartridge prototype,
verify its ability to form the desired cell monolayers, and evaluate the accuracy and precision of counts
performed using the cartridge with our imaging device prototype. Blood samples will span the clinically relevant
range of hematocrit levels to verify device functionality at varying blood viscosities. Accuracy and precision of
the device will be evaluated with samples from healthy patients as well as from patients with neutropenia and
thrombocytopenia to demonstrate acceptable performance for the target patient population. Successful
development of the microfluidic sample cartridge will demonstrate the feasibility of a scalable, robust sample
cartridge for point-of-care hematology analysis. Combined with our existing prototype imaging device and
analysis algorithms, this will demonstrate the feasibility of the proposed hematology analyzer.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
4 SBIR/STTR records share this UEI (2023–2025). Reported award amounts total $2,080,145. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards